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The study of chelating compounds is very important to solve problems related to human metal
overload. 3-Hydroxy-3-pyridinones (HP), namely deferiprone, have been clinically used for chelating
therapy of Fe and Al over the last decade. A multi-disciplinary search for alternative molecules led us to
develop poly-(3-hydroxy-4-pyridinones) to increase metal chelation efﬁcacy. We present herein a
complexation study of a new bis-(3-hydroxy-4-pyridinone)-EDTA derivative with a set of M3+ hard
metal ions (M = Fe, Al, Ga), as well as Zn2+, a biologically relevant metal ion. Thus a systematic
aqueous solution equilibrium study was performed using potentiometric and spectroscopic techniques
(UV-Vis, NMR methods). These set of results enables the establishment of speciﬁc models as well as the
determination of thermodynamic stability constants and coordination modes of the metal complexes.
The results indicate that this ligand has a higher afﬁnity for chelating to these hard metal ions than
deferiprone, and that the coordination occurs mostly through the HP moieties. Furthermore, it was alsoQ1
found that this ligand has a higher selectivity for chelating to M3+ hard metal ions (M = Fe, Al, Ga)
than Zn2+.
1. Introduction
The development of chelating agents for the mobilization ofQ5
excess hard metal ions has been the object of research interest,1,2
either due to high body metal burden owed to metabolic defects
of endogenous metals (e.g. Fe3+) or to exogenous metal ion5
intoxication (e.g. Al3+). In fact, although iron is an essential
element in life, there are many conditions of iron overload
(transfusional iron overload and hemochromatosis), which can
result in iron related toxicity and damage to several organs.3 On
the other hand, aluminium accumulation in some organs can be10
highly toxic, namely in the brain (dialysis encephalopathy) and
also in the bones (osteomalacia).4–6
Desferrioxamine B (DFO) is a naturally occurring trihydrox-Q7
amic acid which has been used for decades as a chelating agent
for the treatment of patients with transfusional iron overload.15
However, the drawbacks associated with this therapy, such as
high cost and low patient compliance associated with its sub-
cutaneous (s.c.) or intravenous (i.v.) daily administration overQ8
several hours, led to the investigation for new chelating drugs.7
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Major advances in the development of new chelators appeared 20
in the 3-hydroxypyridin-4-one (3,4-HP) family of compounds,
namely after the disclosure (ca. 15 years ago) of deferiprone
(DFP, 1,2-dimethyl-3-hydroxypyridin-4-one) as an orally active
drug for the treatment of transfusional iron overload.8 This
family of compounds can be easily made and N-functionalized 25
to allow for the tuning of important physicochemical properties
which enables the selectivity of the biodistribution at different
organs (without disturbing the metal-binding efﬁcacy). A large
number of extra functionalized mono-3,4-HPs have been recently
developed.9–11 However, since they are bidentate ligands, their 30
efﬁcacy as chelating agents requires quite high molar doses to
fulﬁl the coordination to these three charged metal ions.
To overcome the dilution problem and improve the chelating
efﬁciency, a number of polydentate ligands have been developed
by different research groups including ours, namely tris-3,4- 35
HP;12,13 and also bis-3,4-HP derivatives, having two binding units
appended to amino acid skeletons (imino-diacetic acid), to be
used alone14 or in combination with other mono-3,4-HPs in order
to increase the chelating efﬁcacy.15,16 Herein, we present new
results associated with a metal complexation study of another 40
polydentate derivative having two 3,4-HP binding units attached
to ethylenediaminetetraacetic acid (EDTA), while the extra pair
of carboxylic groups could be thought as for eventual metal
extra-coordination or to enable the interaction with bio-sites
(per si or upon extra functionalization). Although this compound 45
(EDTAPr(3,4-HP)2) has already been previously bioassayed,17
we describe herein further studies on the complexation of this
derivative with iron(III) and aluminium(III) in aqueous solution in
view of its potential application as a sequestering agent for these
metal ions, and also the analogous studies with gallium(III) taking 50
into account its use as a radiotracermodel forFe- orAl-overloaded
mice. To evaluate the speciﬁcity of this compound for chelating to
This journal is © The Royal Society of Chemistry 2009 Dalton Trans., 2009, 1–10 | 1
Table 1 Stepwise protonation constants (logK i) for EDTAPr(3,4-HP)2, IDA(3,4-HP)2, 3,4-DMHP and EDDA ligands, as well as the cumulative
formation constants (logb) for their metal(III) complexes (M = Fe, Ga, Al), at I = 0.2 M KCl and T = 25.0 ± 0.1 ◦C; pM valuesa for these compounds
and some other relevant synthetic and biological ligandsQ6
logb
Complex
Ligands logK i MpHqLr (p,q,r) FepHqLr GapHqLr AlpHqLr ZnpHqLr
EDTAPr(3,4-HP)2 (1,-1,1) 22.87(4) — 15.2(3) —
(2,3,3) 95.1(3) — 81.2(2) —
(2,2,3) 89.6(9) 86.53(4) — —
(2,1,3) 82.4(9) 81.22(6) 68.1(5) —
10.12(1) (2,0,3) 73.6(9) 71.82(9) 60.6(6) —
9.53(1) (1,4,1) 40.09(4) 38.6(1) 35.1(2) 36.31(3)
7.04(1) (1,3,1) 38.43(4) 37.19(7) 33.0(1) 33.44(2)
4.03(2) (1,2,1) 37.15(5) 34.22(7) 30.62(9) 29.45(3)
3.38(2) (1,1,1) 34.19(4) 30.7(1) 27.58(7) 21.18(4)
2.84(2) (1,0,1) 29.62(4) — — 11.34(4)
(2,1,1) — — 22.7(2) 27.50(5)
(2,0,1) 37.21(5) — 27.26(9) 21.63(4)
pM 26.3 24.9 19.0 10.7
IDAPr(3,4-HP)2b (2,-2,2) 44.00 — 32.05 —
(1,-1,1) — 18.23 — —
(2,3,3) 89.53 84.97 76.64 —
9.94 (2,2,3) 85.54 80.16 71.72 —
9.44 (2,1,3) 79.90 74.64 66.21 —
5.42 (2,0,3) 74.26 68.44 60.18 —
3.54 (1,3,1) 33.59 33.21 30.44 27.28
3.11 (1,2,1) — — 27.71 —
(1,1,1) 31.16 28.83 25.37 18.93
(1,0,1) 26.16 24.30 20.35 13.30
pM 25.8 22.9 18.8 9.7
3,4-DMHPc (1,0,1) 15.10 13.17 12.20 7.19
9.77 (1,0,2) 26.61 25.43 23.25 13.53
3.68 (1,0,3) 35.88 35.76 32.62 —
pM 19.3 19.4 16.1 16.1
EDDA 9.55(1) (1,-2,1) 3.50(3) 9.33(5) — —
6.48(1) (1,-1,1) — 14.14(2) — —
2.20(1) (1,0,1) 14.99(1) 16.43(4) 10.70(2) 11.1
1.44(2)
pM 17.1 22.9 13.1 9.8
DTPAd pM 24.6 20.9 15.2 14.8
DOTAd pM 24.3 18.8 13.2 17.9
Desferrioxamine (DFB)e , f pM 26.5 22.4 19.3 6.6
Transferrin pM 20.3f I 20.3h 14.5i —
a pM = -log[M] with CL/CM = 10 and CM = 10-6 M; (p,q,r) means a metal complex species with stoichiometry MpHqLr. b Ref. 14. c Ref. 20. d Ref. 19.
e Ref. 21. f Ref. 22. g Ref. 21. h Ref. 23. i Ref. 24.
these hard metal ions, but spearing the biologically relevant zinc,
complexation studies with zinc have also been carried out. The
metal chelation strength and the coordination modes have been
evaluated by potentiometric and spectroscopic methods (UV-Vis
andNMR). SomemolecularmodelingDFT calculations also gave5
support to the coordination modes. Results of in vivo assays are
presented in the assessment of the metal sequestering efﬁciency
(clearing efﬁcacy) of this chelating agent when administered to
an animal model (mice) preloaded with the radiotracer 67Ga–
citrate. The results of the solution and in vivo studies are compared10
with those obtained with other 3,4-HP analogues, including the
currently used iron-chelating drug (DFP).
2. Results and discussion
Protonation of the ligands
To study the metal complexation with EDTAPr(3,4-HP)2, we 15
have used the protonation constants previously reported for
this ligand,17 as depicted in Table 1, which also contains the
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corresponding values for some model compounds (IDAPr(3,4-
HP)2,14 3,4-DMHP,18 and EDDA,19 see Scheme 1).
Scheme 1
Metal complexation
Metal complexation with a model ligand EDDA. The molec-
ular structure of the ligand EDTAPr(3,4-HP)2 is based on two5
hydroxypyridinone moieties connected to a polyaminocarboxylic
scaffold and ethylenediaminetetraacetic acid (EDTA). Besides
the hydroxypyridinone chelating arms, there are still two free
ethylenediamine carboxylates, hereafter named as the EDDA
segment. Since EDDA is also a good chelating agent, we decided10
to start the metal complexation studies with the characterization
of the EDDA–M(III) systems, using our experimental conditions
(I = 0.2 KCl, T = 25 ◦C). An analysis of the potentiometric
titration curves obtained for the different EDDA–M(III) systems
(M = Fe, Al, Ga), at 1 : 1 ligand-to-metal ion ratio (Fig. S1†),15
show that for the Al system the precipitation started at quite
an early stage (ca. pH 3) due to hydrolysis, thus indicating
that EDDA has a low afﬁnity for Al(III) (and that the Al(III)
coordination by EDTAPr(3,4-HP)2 should involve mostly the
hydroxypyridinone groups). In the case of Fe(III) and Ga(III)20
complexation with EDDA, at 1 : 1 molar ratio, the precipitation
occurs at ca. pH 5. Fitting of all the experimental data registered
before the precipitation of the Fe(III)- and Ga(III)-containing
systems resulted in equilibrium models with the absence of any
dinuclear complexes, and formation of only mononuclear species,25
ML, followed by mixed hydroxo species, namely MOHL and
M(OH)2L in both systems. To our surprise, comparison between
the corresponding titration curves obtained for the Fe(III) and
the Ga(III) systems always indicated a slightly higher drop in pH
on the Ga(III) titration curve than on the corresponding Fe(III)30
curve, thus suggesting a higher stability for the gallium complexes.
The calculated cumulative formation constants (Table 1) reﬂect
those curve-proﬁle differences, which are also in agreement with
the literature values (logbFeL = 15.50,20 logbGaL = 18.15,21 L =
EDDA).35
Iron complexation with EDTAPr(3,4-HP)2. The complexation
behaviour of EDTAPr(3,4-HP)2 towards the M3+ hard metal
ions (M = Fe, Al, Ga) in aqueous solutions, was studied by
potentiometric and spectrophotometric techniques at various
ligand-to-metal ion molar ratios. Representative potentiometric 40
titration curves are shown in Fig. 1, for the ligand alone and in the
presence of Fe3+, at 1 : 0.43 to 1 : 1.6 ligand-to-metal ion molar
ratios. Analysis of the titration curves for the binary systems
shows: (i) the existence of a considerable drop in pH at the
beginning of the titration, as compared with that of the ligand, 45
thus indicating high afﬁnity of the ligand for this metal ion and
measurable complexation below pH 2; (ii) if a signiﬁcant amount
of excess ligand is present (L :M = 1 : 0.43), the deprotonation of
the ammonium group (pH range ca. 6–8) does not seem greatly
affected by the presence of the metal ion, thus suggesting that 50
under these conditions only the hydroxypyridinone (HP) moieties
are coordinated to the metal ion, while the “EDDA” part of the
ligand molecule is not involved in the coordination. However,
for a 1 : 1 stoichiometry, there is a change in the titration curves
corresponding to the ammonium deprotonation. Therefore, under 55
these conditions, the eventual interaction between the “EDDA”
part of the ligand and themetal ion could be hypothesized because
the two HP moieties are not enough to complete the coordination
sphere of Fe(III). If metal excess is present, hydrolytic processes
can also occur. 60
Fig. 1 Potentiometric titration curves of aqueous solutions containing
EDTAPr(3,4-HP)2, CL = 2.63 ¥ 10-3 M, alone (), and in the presence
of Fe3+ at: 1 : 0.43 () and 1 : 0.85 (♦) ligand-to-metal molar ratios, CL =
3.50 ¥ 10-3 M; 1 : 1 () and 1 : 1.6 () ligand-to-metal molar ratios, CL =
1.98 ¥ 10-3 M. I = 0.2 M KCl, T = 25.0 ◦C.
Since the coordination of the ligand to Fe(III) starts at pH below
2, the cumulative formation constants of the complex species
formed at such a lowpHwere determinedby spectrophotometry as
previously reported for other bis-hydroxypyridinone ligands.14,22–24
Besides the spectrophotometric titration at very low pH, some 65
other titrations in the whole measurable pH range were made
using different ligand-to-metal ion ratio and some of them are
presented in Fig. 2.
Analysis of the spectra obtained at pH < 2 provided evidence
that the metal coordination starts at very low pH (pH < 0.8) 70
(Fig. S2†) with formation of a mono-chelated species (lmax = 565
nm); at pH 2, the spectra presents a band (lmax = 510 nm) which
can be attributed to the bis-chelated species.14,25,26 Since this is a
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Fig. 2 Absorption spectra registered at different pH values for the EDTAPr(3,4-HP)2–Fe(III) system at: (a) 1 : 1 ligand-to-metal molar ratio, CL = CFe
= 2.78 ¥ 10-4 M, and (b) 2 : 1, with CL = 6.21 ¥ 10-4 M. I = 0.2 M KCl, T = 25.0 ◦C.
Fig. 3 Concentration distribution curves of the Fe-containing species for the system EDTAPr(3,4-HP)2–Fe(III) at: (a) 1 : 1 ligand-to-metal molar ratio
(CL = CFe = 1.65 ¥ 10-4 M); and (b) 2 : 1 ligand-to-metal molar ratio (CL = 6.21 ¥ 10-4 M, CFe = 3.01 ¥ 10-4 M). pH dependence of lmax (), molar
absorptivity (e,) of UV-Vis spectra, and molar magnetic moment (m) of [Fe(III)–EDTAPr(3,4-HP)2] complexes. I = 0.2 M KCl, T = 25.0 ◦C.
charge transfer (CT) band between the hydroxypyridinone oxygen
atoms and Fe3+, and no spectral changes are expected from the
deprotonation of the amine nitrogen of the “EDDA” part of
the molecule, it is not possible to infer about the involvement
of the “EDDA” moiety in the metal coordination. Above pH5
2, both the stoichiometric systems presented blue-shifts of the
CT absorption bands, thus indicating the formation of species
with increased number of coordinating units around the metal
ion. Spectral bands with lmax = 460 nm are characteristic of
tris-chelated species (three hydroxypyridinone units coordinated10
to the Fe3+ metal ion).14,25,26 However, there is no possibility
to saturate all of the six coordination sites by one ligand via
hydroxypyridinonate type chelates. Therefore, under these ligand-
to-metal stoichiometric conditions (2 : 1), it can be assumed that
one ligand molecule can bridge two bis-chelated iron centers to15
complete their coordination sphere, which should correspond to
the formation of dinuclear species Fe2HxL3 (x = 0,1,2,3). On
the other hand, mixed hydroxypyridinone–ligand–hydroxo species
(with m2-hydroxo bridged bonds) have also been reported with a
similar lmax value.14 Under the experimental spectrophotometric20
conditions, the occurrence of precipitation was not observed. The
ﬁtting analysis of the experimental spectra with equilibrium mod-
els (PSEQUAD program)27 allowed the calculation of cumulative
formation constants presented in Table 1, and agreement between
simulated and experimental spectra of some complex species (Fig.25
S2†) also gave support to the assumed equilibrium models. The
calculated cumulative formation constants allowed the calculation
of the concentration distribution species with pH depicted in Fig.
3. This ﬁgure also shows the dependence of the lmax and of the
molar absorptivity on the pH, where values are according to the 30
expected ones for the corresponding model complex species. The
variation of the magnetic moment along the same range of pH
measured under the same conditions used for the complexation
studies, is also included therein, which is aimed at elucidating the
presence of dinuclear iron(III) complexes. 35
At T = 298 K, for the 1 : 1 stoichiometry (Fig. 3(a)), the
measured magnetic moments mM (ca. 6MB) are in agreement with
reported values for non-interacting mono-ferric complexes in the
solid state (5.9 MB).28 On the other hand there is no appreciable
decrease in the value along the studied pH range indicating 40
the absence of dinuclear species with strong anti-ferromagnetic
interactions between the two Fe(III) sites, namely binuclear species
with bridging hydroxo groups, m2-oxo species (mM = 3.4 MB, at
300 K).29 Also for the 1 : 2 stoichiometric conditions (Fig. 3(b)),
up to pH7, there is no variation inmM, indicating that the dinuclear 45
species should have the ferric centres separated enough to prevent
any strong anti-ferromagnetic interactions. Above that pH, some
decreasing is observed in mM, which can be due either to the
formation of some bridging hydroxo groups or, most probably,
just to some undetected minor precipitation of hydroxo–ligand 50
mixed complex species.
Aluminium(III) complexation with EDTAPr(3,4-HP)2. To
study the EDTAPr(3,4-HP)2–Al(III) system, potentiometric titra-
tions were carried out at 2 : 1 and 1 : 1 ligand-to-metal ion
ratios (Fig. 4). Analysis of the potentiometric curve for the 1 : 1 55
stoichiometric conditions indicates that the complex formation
starts at pH ca. 2, most probably with formation of a mono-
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Fig. 4 Potentiometric titration curves of aqueous solutions containing
EDTAPr(3,4-HP)2, CL = 2.63 ¥ 10-3 M, alone (), and in the presence of
Al3+, at the ligand-to-metal molar ratios: 1 : 0.5 (♦) and 1 : 1 (); CL =
3.50 ¥ 10-3 M. I = 0.2 M KCl, T = 25.0 ◦C.
chelated species, AlH4L, containing only one hydroxypyridinone
group coordinated to the metal ion, with eventual coadjuvation of
one carboxylic group.
Stepwise release of one proton from the EDDA backbone and
two protons from the second hydroxypyridinone moiety leads to5
the formation of the bis-chelated species (AlL). The fact that the
release of the fourth proton from the complexes seems to occur
at a lower pH (ca. 4) than for the ammonium proton of the free
ligand (pK = 7.04) could be due to either the interaction of the
carboxylate with the metal ion (so the ammonium proton could10
be pushed by the metal ion) or, most probably, to some hydrolytic
process (so the species formed could actually be Al(OH)LH
instead of AlL). For the 1 : 2 stoichiometry, tris-chelated species
are expected to be formed as 2 : 3 dimeric species, Al2HxL3, (x =
0, 1, 2, 3). The formation of the bis-chelated complex with Al(III)15
starts at ca. pH = 2 with subsequent stepwise deprotonation with
increasing pH. Fitting analysis of the titration curve leads to an
equilibrium model involving mononuclear and binuclear species
(see Table 1) in different ratios, depending on the stoichiometric
conditions. The logb values calculated for the different complex20
species with this tetradentate ligand are consistent with the
corresponding values for the bidentate analogue (3,4-DMHP)
(Table 1). Representative examples of concentration distribution
curves for the Al(III) containing system are shown in Fig. 5.
Aimed at gaining some support for the assumed equilibrium25
models, 1H NMR spectra were also registered for the ligand
EDTAPr(3,4-HP)2 alone, and in the presence of Al(III) at 1 : 1 and
1 : 3 (M :L) stoichiometry, at different pH values. Comparison of
the spectra registered for the ligand and for the complex systems
at both ratios, showed a clear change in chemical shifts of the 30
peaks corresponding to the hydroxypyridinone, but no change in
the proton peaks of the “EDDA” part of the ligand molecule
(Fig. S3†). These results are especially relevant for the 1 : 1
stoichiometry, indicating that the ligand-to-Al(III) coordination
does not involve the EDDA arm, but only the hydroxypyridinone 35
moieties. The titration stopped at ca. pH 4 due to precipitation,
which can be a result of the formation of the hydrolytic species
(eventually Al(OH)LH instead of AlL) and so the hydrolysis Q10
might start before the deprotonation of the ammonium proton.
The changes induced on the aromatic hydroxypyridinone protons 40
by the Al-complexation are clearly shown in Fig. 6, providing
evidence for the involvement of the pyridinone arms in the metal
ion coordination. Deconvolution of the 1H NMR spectra for
the Al–ligand system at different pH values by the Mestre C
program30 allowed a comparative analysis of the relative intensities 45
Fig. 6 1H NMR spectra at indicated pD corresponding to the hydrox-
ypyridinone ring protons of solutions containing EDTAPr(3,4-HP)2 and
Al3+ at 1 : 1 ligand-to-metal molar ratio, CL = 2.0 ¥ 10-2 M.
Fig. 5 Concentration distribution curves of the Al-containing species for the system EDTAPr(3,4-HP)2–Al(III) at ligand-to-metal molar ratios: (a) 1 : 1
and (b)2 : 1; CL = 3.5 ¥ 10-3 M. I = 0.2 M KCl, T = 25.0 ◦C.
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Table 2 Calculated relative percentage of the 1H NMR peaks speciﬁed. The values in parenthesis represent the species percentage given by theQ9
potentiometric result for the same conditions (CL = CAl = 2 ¥ 10-2 M)
Peaks pD* = 0.87 pD* = 1.38 pD* = 2.39 pD* = 2.82 pD* = 3.47 pD* = 4.79 Attributions
A 100 (100) 83 (92) 24 (12) 3 (2) — — Free hydroxypyridinone
B — 17 (8) 52 (48) 67 (68) 37 (33) — AlHxL (x = 2, 3, 4)
C — — 24 (33) 30 (30) 53 (67) 100 (100) AlHxL (x = 0, 1)
Fig. 7 Absorption spectra registered at different pH values for (a) the ligand EDTAPr(3,4-HP)2 alone, CL = 1.0 ¥ 10-4 M; (b) for the
EDTAPr(3,4-HP)2–Ga(III) system at 2 : 1 ligand-to-metal ion molar ration, CL = 5.25 ¥ 10-5 M, CGa = 2.01 ¥ 10-5 M. I = 0.2 M (KCl, HCl), T =
25.0 ◦C.
Fig. 8 Concentration distribution curves of the Ga-containing species for the system EDTAPr(3,4-HP)2–Ga(III) at the ligand-to-metal molar ratios:
(a) 1 : 1 and (b) 2 : 1; CL = 5.25 ¥ 10-5 M. I = 0.2 M KCl, T = 25.0 ◦C.
of the individual peaks with the species distribution curves and
enabled a rough peak attribution to the species in solution. Table
2 includes the calculated relative percentages for each peak, and
their assignment to the corresponding species. We can conclude
that there is a reasonably good ﬁt between the values obtained for5
the concentration distribution species on the basis of the 1HNMR
spectroscopic signals and the potentiometric results.
Ga(III) complexation with EDTAPr(3,4-HP)2. For this com-
plexation study, only spectrophotometry was used instead of
pH-potentiometry because the higher concentration conditions10
demanded for this technique led to precipitation. Although no
characteristic bands belong to the Ga(III) complexes, comparison
between the spectra obtained for the ligand alone and in the
presence of the metal ion (Fig. 7), suggests considerable changes
due to the formation of a complex species with high stability.15
Fitting analysis of the spectra obtained at different pH values
and various ligand-to-metal ion stoichiometric conditions was
performed with the PSEQUAD program,27 in which the input Q11
ﬁle calculated the molar absorptivity of the ligand which was
included as ﬁxed data. Since this spectra analysis involves only 20
data from the ligand itself, the corresponding mathematical ﬁtting
was more difﬁcult than for the other complex systems; however,
it was possible to ﬁnd a self-consistent equilibrium model, where
the complex species and stability constants are presented in Table
1 and the corresponding concentration distribution curves are 25
depicted in Fig. 8.
Molecularmodeling studies. In order to obtain some structural
information on the aluminium complex, a molecular modeling
study was performed based on molecular mechanics, AM1 semi-
empirical, and DFT calculations. These methods were systemati- 30
cally employed31 for this type of molecular systems.
To obtain the ﬁnal structure, we applied a general procedure
presented in the specialized literature.32–34 Brieﬂy, the starting
structures generated by the CAChe editor35 were ﬁrstly optimized
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by the MM3 method. The most stable conformer obtained for
every case was successively optimized by AM1 (vacuum) and
AM1 (COSMO) methods. Finally, for the most stable conformer
found by this last method, its geometric optimization was carried
out using the Density Functional Theory and the B3LYP hybrid5
functional, in the Gaussian03 program.36
Due to the complexity of the computed structures,DFT calcula-
tions were performed in two steps: ﬁrstly, a structure was obtained
using the STO-3G basis set and its geometry optimization was
further reﬁned during the second step, using a more accurate basis10
set, namely 6-31G**. No symmetry constraints were enforced
during geometry optimization. Both methods indicate the same
type of structure for the most stable AlL complex, and Fig.
9 presents the most stable conformer obtained by the DFT
calculations.15
Fig. 9 The most stable conformer of the aluminium complexes obtained
by the DFT calculations.
The only difference is in the numerical value of the en-
ergy (-2533.0398418 Hartree using STO-3G and -2566.0642645
Hartree using 6-31G**). It can be seen from the structure that
the coordination of the aluminium atom involves two hydrox-
ypyridinone arms (2¥{O,O}). The other two extra-coordinating20
sites are satisﬁed by two water molecules. No other part of the
EDTA moiety is involved in the complexation of aluminium.
An interesting aspect is that even without symmetry constraints
imposed, the aluminiumatomadopts an octahedral conﬁguration.
The computed structure shows a very good agreement with the25
theory and it is extremely well correlated with the experimental
NMR data that we obtained.
Chelating selectivity of the EDTAPr(3,4-HP)2. As a potential
Fe(III)- and Al(III)-chelating agent, EDTAPr(3,4-HP)2 should
present a high afﬁnity and speciﬁcity for these M(III) to allow 30
for their decorporation without depletion of other bioavailable
essential metal ions such as Zn(II). Therefore, EDTAPr(3,4-HP)2–
Zn(II) complexation studies were also performed by potentio-
metric titrations at different stoichiometric conditions. From the
potentiometric titration curves (Fig. S4†), it was not clear whether 35
there was any involvement of the “EDDA” part of the molecule in
the coordination of the Zn(II) metal ion. There was some change
in the shape of the titration curves but for pH values at which the
hydrolysismay also occur. Theﬁtting of those titration curves leads
to stability constant values (Table 1) and the species distribution 40
curves (Fig. 10).
In order to gain a better understanding of the coordination
modes involved in this equilibrium system, some 1H NMR studies
were made. The 1H NMR titration curves of the ligand in a D2O
solution was compared with two sets of 1H NMR titration curves 45
of the EDTAPr(3,4-HP)2–Zn(II) system at 1 : 1 and 1 : 2 ligand-
to-metal ion molar ratios. A comparative analysis of both sets of
spectra (see spectra for selected pD in Fig. S5†) show that there
are interactions with both parts of the molecule (the “EDDA”
part and the hydroxypyridinone moieties), as indicated by the 50
changes in the NMR peaks corresponding to these two molecular
segments.
A detailed analysis of those spectra show that at low pH (pD ca.
0.6–0.7) there is no appreciable modiﬁcation of the ligand spectra
in the presence of the metal ion. At pD = 1.5–1.7, some changes 55
in the peaks corresponding to the EDDA skeleton are noticeable,
increasing with pH. At higher pH (pD ca. 3.7–4.6), a number
of changes were observed in the aromatic region of the spectra,
indicative of the participation of the hydroxypyridinone groups
in the zinc coordination, although there are still some changes in 60
the spectra with regards to the “EDDA” skeleton, which indicates
interactions of that molecular segment with the metal ion.
From all those observations, we can say that the zinc coordi-
nation starts with the “EDDA” skeleton of the ligand molecule
but ﬁnishes with a bis-hydroxypyridinone coordination mode. 65
In fact, the logb value (37.19) obtained for the ﬁrst complex
species (ZnH4L) is in agreementwith aEDDA–Zn(II) coordination
contribution (ca. 11) plus the pKa values of the four hydrox-
ypyridinones protons. The subsequent deprotonation processes
Fig. 10 Concentration distribution curves of the Zn-containing species for the system EDTAPr(3,4-HP)2–Zn(II) at the ligand-to-metal molar ratios:
(a) 1 : 1 and (b) 1 : 2; CL = 3.0 ¥ 10-3 M. I = 0.2 M KCl, T = 25.0 ◦C.
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Fig. 11 pAl versus pH for the systems: Al(III)–EDTAPr(3,4-HP)2, Al(III)–3,4-DMHP, Al(III)–DTPA, Al(III)–citrate and Zn(II)–EDTAPr(3,4-HP)2 and
Zn(II)–DTPA; pM = -log[M] with CL/CM = 10 and CL = 1 ¥ 10-5 M.
are according to the stepwise release of two pyridinium pro-
tons, affording ZnH3L and ZnH2L; the ﬁnal hydroxypyridinone
deprotonation/coordination starts at ca. pH = 6, leading to
the formation of hydroxypyridinone bis-chelated species. Such a
behaviour can be rationalized by the fact that the aminoacid is the5
less basic group and so zinc can compete with the corresponding
protons in acidic conditions whereas, at neutral pH conditions,
the hydroxypyridinone chelates are much more stable that those
with the EDDA moiety.
Comparative analysis of the complexation ability10
A comparison between the metal (M) chelating afﬁnities of
the ligands with different proton dependency and denticity can
be made on the basis of pM values (pM = -log[M] with
CL/CM = 10 and CM = 10-6 M) at a speciﬁc pH, usually the
physiological pH (7.4). Therefore, pM values were calculated15
for the metal systems with the ligand in study as well as for
a set of common synthetic and biological ligands (see Table
1). It is clearly shown that under micromolar conditions that
prevail in biological systems, EDTAPr(3,4-HP)2 presents a much
higher metal chelating efﬁcacy than the mono-hydroxypyridinone20
derivative, 3,4-DMHP (deferiprone) (DpFe = 7). Thus, it can be
predicted to be a better scavenger for these type of hard metal
ions than deferiprone. It also presents a slightly higher chelating
ability than the bis-hydroxypyridinone analogue, IDAPr(3,4-
HP)2,14 which may be due to the higher ﬂexibility of the present25
ligand. Additionally, EDTAPr(3,4-HP)2 shows a much higher
chelating efﬁcacy and speciﬁcity for these M3+ metal ions than
some of the polyaminocarboxylate ligands (DPTA and DOTA19)
with clinical applications in imaging with 68Ga. The present ligand
shows a chelating strength similar to that of DFO for this set30
of metal ions,37,38 while from complexation data with transferrin
(Table 1) it seems likely that EDTAPr(3,4-HP)2 can compete
with apotransferrin for this set of metal ions.39–41 However, since
the mono-hydroxypyridinone deferiprone proved to be able to
mobilize iron from several iron-containing proteins such as ferritin35
and transferring,42 an identical role can be postulated for the
present di-hydroxypyridinone, eventuallywith evenhigher efﬁcacy.
Concerning the Zn-afﬁnity, the polyaminocarboxylate ligands
with clinical applications (DOTAandDTPA)19 present the highest
values, followed by the aminocarboxylic-hydroxypyridone ligand,40
EDTAPr(3,4-HP)2, as expected. Although the difference between
the Al- and Zn-chelating afﬁnities of the present ligand (DpM =
8.2) is lower than that found for 3,4-DMHP (DpM = 9.9), the
difference is still high enough to conclude that the EDTAPr(3,4-
HP)2 ligand is a strong and selective Al-chelating agent under 45
physiological pH conditions. In the case of Fe(III), this selectivity
is evenbetterwith thebis-chelated ligand,withDpM= 15.7 instead
of the 13.1 of 3,4-DMHP. A further comparison between the Al-
chelating afﬁnities of several ligands and the Al/Zn chelating
selectivity, along a wide pH range (2–9), is also graphically 50
illustrated in Fig. 11(a) and 11(b), respectively. Fig. 11(a) shows
that the new chelating agent presents the highest Al-afﬁnity along
a wide pH range (3.5–9), in opposition to deferiprone (3,4-
DMHP) which, for acidic-neutral pH conditions, is overcome by
the aminocarboxylic ligand (DTPA). Fig. 11(b) conﬁrms the high 55
Al/Zn selectivity of the new chelating agent in a wide range of
pH, excluding the acidic (pH < 4).
Biodistribution studies. The results on the whole body 67Ga
excretion data for the complexes are presented in Fig. 12 as a
percentage of the injected dose, illustrating the main differences 60
between the 67Ga–(3-hydroxy-4-pyridinone) complexes and that
of 67Ga–citrate.
Fig. 12 Whole body excretion expressed as a percentage of injected
dose (% I.D) of 67Ga–citrate, 67Ga–3,4-DMHP, 67Ga–IDAPr(3,4-HP)2, and
67Ga–EDTAPr(3,4-HP)2 complexes, 5, 15, 30, 60, 1440 and 2880 min after
intravenous administration of the radiotracer in female mice (n = 3–5).
The administration of a 67Ga–EDTAPr(3,4-HP)2 complex solu-
tion interfereswith the normal biological distribution proﬁle of the
tracer leading to a highly increased excretion rate of radioactivity 65
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from the whole animal body, as compared with the excretion
of the 67Ga–citrate form, similar to the results obtained with
other bis-(3-hydroxy-4-pyridinone) ligands, IDAPr(3,4-HP)2.14
Thus, the enhancement of the 67Ga excretion rate is probably
due to the higher metal-binding afﬁnity of these aminoacid-5
bis(hydroxypyridinone) ligands, as compared to that of citrate and
themono-hydroxypyridinone, 3,4-DMHP. (More details about the
biodistribution proﬁle are published in ref. 17).
3. Experimental
Materials and methods10
All the reagents used were analytical-grade commercial reagents.
The ligand, EDTAPr(3,4-HP)2, was synthesized according to stan-
dard synthetic methodologies,17 although in the present synthesis
the puriﬁcation of the compound also involved a chromatographic
separationwith Shephadex (LH20) usingwater (pH= 7) as eluent.15
Potentiometric and spectrophotometric studies
Reagents and solutions. Aqueous stock solutions of M(III) (M
= Fe, Ga, Al) were prepared from the corresponding chloride
salts. ZnO (Reanal) was dissolved in a known amount of HCl
solution (0.1 M). The exact concentration of the metal ion was20
calculated gravimetrically via precipitation of the quinolin-8-
olate and the containing acid was determined by potentiometric
titration. The titrant was non-carbonated 0.2 M KOH solution,
which was standardized with a 0.025 M potassium hydrogen
phthalate solution, using the Gran’s method.4325
Potentiometric measurements. The potentiometric measure-
ments were performed with a MOLSPIN pH-Meter, equipped
with a Metrohm 6.0234.100 combined electrode and a Mol-AcS
microburete controlled by a computer at 25.0 ◦Cand ionic strength
I = 0.2 M (KCl). To calibrate the electrode, the method described30
by Irving et al. was used44 which meant that the pH-metric
reading could be converted into hydrogen ion concentration. The
water ionization constant, Kw, was found to be 10-13.76 under the
conditions employed. All the samples were CO2-free by passing
argon on the top of the sample in the potentiometric cell. The35
pH-metric titrations were performed throughout the pH range
~= 2.0–11.0. All titrations started at pH ~2 after the addition of
the necessary amount of acid. Samples of 3.0 mL were used. The
ligand concentrations were varied in the range 1.00–3.50 ¥ 10-3 M.
Different ligand-to-metal ion molar ratios were used (2 : 1, 1 : 1,40
1 : 2).
Spectrophotometric measurements. A HP 8453 spectropho-
tometer was used to record the spectra in the region 250–800 nm.
The ligand concentrations were varied in the range 10-5–10-3 M.
Different ligand-to-metal ion ratioswere used (2 : 1, 1 : 1, 1 : 2). The45
pH values were measured using a MOLSPIN pH-Meter equipped
with a Metrohm 6.0234.100 combined electrode.
Calculations. The proposed equilibrium models were based
on the chemical structure of the ligand and the calculations of
the overall stability constants, bMpHqLr = [MpHqLr]/[M]p[H]q[L]r.50
They were obtained by ﬁtting analysis of the titration data with
the PSEQUAD computer program27 and using the literature data
for the hydrolytic species.45,46 The selection of the equilibrium
models was based on the critical analysis of the weighted residuals,
the statistical parameters (c2, s)47 and graphical comparisons 55
between the experimental and simulated potentiometric curves.
For very acidic conditions (pH < 2), the stability constants of
the corresponding Fe(III) and Ga(III) complexes were calculated
from the spectrophotometric data using the PSEQUAD program.
The results were accepted for the ﬁtting parameter smaller than 60
2 ¥ 10-2. The HYSS program48 was used to get the concentration
distribution curves.
1H NMR measurements
1H NMR titrations were performed in a Varian Unity 300
spectrometer at probe temperature. The samples were prepared 65
in D2O and the pD was measured with a Thermo Orion 420A pH
meter and a Mettler Toledo (U402-M3-S7/200) micro-electrode.
Since the electrode was calibrated with standard buffer aqueous
solutions, pH* is the direct value measured by the pH meter and
the ﬁnal pD was calculated as pD = pH* + 0.4.49 The pH* 70
change was performed with DCl and KOD solutions diluted
in D2O. Chemical shifts (d ppm) were measured using sodium
3-(trimethylsilyl)-[2,2,3,3–2D4]propionate (DSS) as an internal
reference (d = 0 ppm). The iron(III)molarmagnetic susceptibilities
(cM) were measured in D2O solution as a function of pD by 75
the Evans method,50 and the corresponding magnetic moments
were calculated (mM = 2.84(cMT)1/2),51 for both the Fe(III) : L
stoichiometries under the same experimental concentration con-
ditions used for the potentiometric measurements, andT = 298K.
4. Conclusions 80
The complex formation of an aminocarboxylic-bis-
hydroxypyridinonate ligand, EDTAPr(3,4-HP)2, was studied
in aqueous solution, and the results demonstrate that in a
wide pH range, and diluted conditions prevailing in vivo, this
new compound has a higher efﬁcacy for chelating hard metal 85
ions (e.g. Fe3+, Ga3+, Al3+) than the mono-hydroxypyridinone,
deferiprone (a drug clinically used), and also some bioligands
(e.g. citric acid and transferrin). The excellent solution properties
of this compound, namely the balanced hydrophilicity, high
complexation ability towards iron and aluminium, and its 90
good Fe/Zn and Al/Zn selectivity, together with the in vivo
behaviour, namely the favourable biodistribution pattern of this
new chelating agent with rapid clearance of 67Ga-overload mice
from main organs and the high rate of metal excretion, suggest its
potential usefulness as an in vivo Al- and Fe-decorporating agent, 95
without zinc depletion.
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